Mylan Loses Bid To Stall Trial Over Neurim's Melatonin Patent
A judge has refused generic-drug maker Mylan's request to stay Neurim's patent infringement litigation to wait for a European Patent Office ruling on the validity of the Israeli pharmaceutical company's melatonin...To view the full article, register now.
Already a subscriber? Click here to view full article